Public scrutiny and the increasing number of projects addressing later stages of the research and innovation process announced the need for an enhanced attention to be paid to identify and address ethics concerns. Ex-ante ethics review as implemented in EU-funded health research and a proactive ethics management are a genuinely useful exercise and ensures top-quality research, from the lab to the patient.
Get full access to this article
View all access options for this article.
References
1.
Decision No 1982/2006/EC of the European Parliament and of the Council of 18 December 2006 concerning the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007–2013). Official Journal of the European Union L 412/1 of 30December2006.
2.
Gans-CombeC, HoughtonJ, KurtzA, CarvalhoAS and HermerenG. (2014). Health Ethics Screening Assessment: Health Ethics Screening Impact Analysis–FP6/FP7. A working group report. Publication expected in November2014.
3.
Campo-RuizV, ed. (2013). Human Stem Cell Research and Regenerative Medicine. European Science Foundation, Strasbourg, France.
4.
Regulation (EU) No. 1291/2013 of the European Parliament and of the Council of 11 December 2013 establishing Horizon 2020—the Framework Programme for Research and Innovation (2014–2020) and repealing Decision No 1982/2006/EC. Official Journal of the European Union L 347/104 of 20December2013.
5.
HugK and HermerénG. (2012). Which patient groups should be asked to participate in first-in-human trials of stem-cell-based therapies?. J Clin Ethics, 23:256–271.
6.
HugK and HermerénG. (2013). Differences between Parkinson's and Huntington's diseases and their role for prioritization of stem cell-based treatments. Curr Mol Med, 13:777–791.
